Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Актуальная терапия инфекционных заболеваний кожи и подкожно-жировой клетчатки
________________________________________________
Dvoriankova E.V. Relevan treatment of infectious diseases of the skin and subcutaneous fat. Gastroenterology. Surgery. Intensive care. Consilium Medicum. 2018; 2: 60–64.
DOI: 10.26442/26583739.2018.2.180128
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: инфекция кожи, золотистый стафилококк, метициллин-резистентность, сульфатиазол серебра.
________________________________________________
Infectious diseases of the skin and subcutaneous fat represent a large cluster of common types of infection. They include abscesses, cellulitis, secondarily infected wounds which require immediate effective and timely antibacterial treatment. However, selection of antibiotic therapy can be a very difficult task if an infection disease is caused by methicillin-resistant strains of microorganisms or there are treatment risk factors or if a patient refuses treatment. The use of combined topical silver – containing antibacterial drugs provides an adequate management of infectious skin diseases and prevention of methicillin-resistance development.
Key words: skin infection, Staphylococcus aureus, methicillin-resistance, silver sulfathiazole.
2. Patti JM, Allen BL, McGavin MJ, Hook M. MSCRAMM-mediated adherence of microorganisms to host tissues. Annu Rev Microbiol 1994; 48: 585–617.
3. Garau J, Ostermann H, Medina J et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect 2013; 19: E377–E385.
4. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1–12.
5. Jokinen E, Laine J, Huttunen R et al. Trends in incidence and resistance patterns of Staphylococcus aureus bacteremia. Infect Dis (Lond) 2018; 50 (1): 52–8.
6. Pichereau S, Rose WE. Invasive community-associated MRSA infections: epidemiology and antimicrobial management. Expert Opin Pharmacother 2010; 11 (18): 3009–25.
7. Lin MY, Hayden MK, Lyles RD et al. Prevention Epicenters Program, Centers for Disease Control and Prevention. Regional Epidemiology of Methicillin-Resistant Staphylococcus aureus Among Adult Intensive Care Unit Patients Following State-Mandated Active Surveillance. Clin Infect Dis 2018; 66 (10): 1535–9.
8. Rosen J, Landriscina A, Kutner A et al. Silver sulfadiazine retards wound healing in mice via alterations in cytokine expression. J Invest Dermatol 2015; 135 (5): 1459–62.
9. Jodar KS, Balcão VM, Chaud MV et al. Development and characterization of a hydrogel containing silver sulfadiazine for antimicrobial topical applications. J Pharm Sci 2015;
104 (7): 2241–54.
10. Самцов А.В., Теличко И.Н., Стаценко А.В., Хайрутдинов В.Р. Применение наружных средств, содержащих соединения серебра, в терапии больных пиодермиями. Вестн. дерматологии и венерологии. 2014; 1: 7580. / Samtsov A.V., Telichko I.N., Statsenko A.V., Khairutdinov V.R. Primenenie naruzhnykh sredstv, soderzhashchikh soedineniia serebra, v terapii bol'nykh piodermiiami. Vestn. dermatologii i venerologii. 2014; 1: 7580. [in Russian]
________________________________________________
1. Cheung AL, Wolz C, Yeaman MR, Bayer AS. Insertional inactivation of a chromosomal locus that modulates expression of potential virulence determinants in Staphylococcus aureus. J Bacteriol 1995; 177: 3220–6.
2. Patti JM, Allen BL, McGavin MJ, Hook M. MSCRAMM-mediated adherence of microorganisms to host tissues. Annu Rev Microbiol 1994; 48: 585–617.
3. Garau J, Ostermann H, Medina J et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect 2013; 19: E377–E385.
4. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1–12.
5. Jokinen E, Laine J, Huttunen R et al. Trends in incidence and resistance patterns of Staphylococcus aureus bacteremia. Infect Dis (Lond) 2018; 50 (1): 52–8.
6. Pichereau S, Rose WE. Invasive community-associated MRSA infections: epidemiology and antimicrobial management. Expert Opin Pharmacother 2010; 11 (18): 3009–25.
7. Lin MY, Hayden MK, Lyles RD et al. Prevention Epicenters Program, Centers for Disease Control and Prevention. Regional Epidemiology of Methicillin-Resistant Staphylococcus aureus Among Adult Intensive Care Unit Patients Following State-Mandated Active Surveillance. Clin Infect Dis 2018; 66 (10): 1535–9.
8. Rosen J, Landriscina A, Kutner A et al. Silver sulfadiazine retards wound healing in mice via alterations in cytokine expression. J Invest Dermatol 2015; 135 (5): 1459–62.
9. Jodar KS, Balcão VM, Chaud MV et al. Development and characterization of a hydrogel containing silver sulfadiazine for antimicrobial topical applications. J Pharm Sci 2015;
104 (7): 2241–54.
10. Samtsov A.V., Telichko I.N., Statsenko A.V., Khairutdinov V.R. Primenenie naruzhnykh sredstv, soderzhashchikh soedineniia serebra, v terapii bol'nykh piodermiiami. Vestn. dermatologii i venerologii. 2014; 1: 7580. [in Russian]
ФГБУН «Центр теоретических проблем физико-химической фармакологии» РАН. 119991, Россия, Москва, Ленинский пр-т, д. 38а, корп. 1
*dvoriankova@mail.ru
________________________________________________
E.V.Dvoriankova*
Center for Theoretical Problems of Physicochemical Pharmacology of the Russian Academy of Sciences. 119991, Russian Federation, Moscow, Leninskiy pr-t, d. 38a, korp. 1
*dvoriankova@mail.ru